<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732586</url>
  </required_header>
  <id_info>
    <org_study_id>Hospitalgea</org_study_id>
    <nct_id>NCT03732586</nct_id>
  </id_info>
  <brief_title>Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis</brief_title>
  <official_title>Effect of Omega-5 Fatty Acid Supplement on Markers of Inflammation and Oxidative Stress in Patients With Severe Alcoholic Hepatitis Treated With Prednisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Dr. Manuel Gea González</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Dr. Manuel Gea González</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Mexico, alcoholic liver disease is the fourth cause of mortality (INEGI). Patients with
      severe alcoholic hepatitis have a high mortality at 28 days and 6 months, patients receiving
      standard treatment with prednisone that are non responders (Lille&gt; 0.45) have a survival of
      53.3 ± 5.1 % to 28 days. At present, there is not a completely effective treatment this non
      responders patients, with a high mortality, so it is necessary to look for other therapeutic
      strategies.

      The omega-5 fatty acid (punicic acid) has been considered a powerful antioxidant, it is an
      agonist of PPAR gamma, has been shown to reduce lipid peroxidation, and restore levels of
      antioxidant enzymes such as superoxide dismutase (SOD), catalase and glutathione peroxidase.
      It has also been shown to inhibit the expression of proinflammatory cytokines (such as IL6,
      IL8, IL23, IL12 and TNFalpha) through PPAR and modulation delta.

      The objective of this study is to evaluate the effect of Omega 5 fatty acid on inflammatory
      markers and antioxidant-oxidant balance markers in patients with severe alcoholic hepatitis
      treated with prednisone. HYPOTHESIS. Omega 5 fatty acid being a PPARgamma agonist reduces
      lipid peroxidation and protein damage, restoring reduced glutathione levels, as well as
      decreasing proinflammatory cytokines, in patients with Severe Alcoholic Hepatitis treated
      with prednisone and supplementation with fatty acid Omega 5.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind clinical trial.

      Two groups:

        -  GROUP A (standard treatment): Prednisone 40 mg a day + Placebo (manufactured by the same
           laboratory with the same presentation and physical appearance as the nanoemulsified
           pomegranate seed oil rich in Omega 5 fatty acid)

        -  GROUP B (combined treatment): Prednisone 40 mg per day + nanoemulsified pomegranate seed
           oil rich in Omega 5 fatty acid (2 capsules of 0.64g each / day).STUDY UNIVERSE:
           Patients&gt; 18 years old, indistinct gender, with a diagnosis of severe alcoholic
           hepatitis.

      STUDY POPULATION: Patients with clinical and laboratory diagnosis of alcoholic hepatitis
      Severe Maddrey score ≥32.

      SAMPLE SIZE: Double blinded clinical trial, which will include 20 patients for standard
      treatment and 20 patients for combined treatment, patients who meet the inclusion criteria
      will be invited to participate. If you agree to participate (after signing the informed
      consent), the AUDIT C and CAGE questionnaires will be applied, as well as the measurement of
      anthropometric values and the taking of 3 blood tubes (2 purple and 1 yellow) for the
      measurement of cytokines, markers of oxidative stress, lipid peroxidation and protein
      carbonyls.

      The initial evaluation will include liver ultrasound, heart rate, blood pressure,
      temperature, anthropometric evaluation (weight, height, BMI), evaluation of ascites
      (abdominal circumference), hepatic encephalopathy (West Haven Scale). Alcohol abuse will be
      assessed using the AUDIT and CAGE score. Start-up laboratories will be carried out: TP, INR,
      Complete liver function tests (BT, BD, FA, AST, ALT, GGT, Albumin), Seric electrolytes (Na,
      K, Phosphorus, Magnesium), Creatinine, Blood cytometry (Leukocytes (PMN) ), hemoglobin, VCM,
      platelets), lipid profile (ColT, HDL, LDL, TGs), ferritin and transferrin saturation,
      Anti-nuclear antibodies, Anti mithocondrial antibodies, AgHBs, AcHBc, anti HCV, anti HIV. The
      scrutiny of bacterial infections will be carried out through urine culture, blood cultures
      and in case of suspicion of SBP (parascentesis). Child-Pugh score (A5-6, B7-9, C10-12),
      Maddrey score, MELD, ABIC score, Glasgow score. Chest x-Ray, General Urine Test.

      Patients who meet the inclusion criteria, previously described, will be proposed to
      participate in the study, explaining in detail the procedures as well as the studies to be
      carried out. If they agree to participate, they will proceed to sign the informed consent of
      the patient and their family member. responsable. Samples (2 yellow tubes and 2 purple tubes)
      will be taken for the measurement of cytokines, markers of oxidative stress, lipid
      peroxidation and protein carbonyls prior to the supply of the supplement vs placebo as well
      as the start of standard treatment. It will be explained to the patient that these samples
      will be done in 4 times (at diagnosis, on day 7, 14 and 28), which will be carried out during
      their hospitalization and follow-up.

      Both treatments will be taken for 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blind clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subjects will be randomly assigned to one of the two treatments. The randomization is done through a computer generated system. The labeling will be done by a pharmacist or similar. Envelopes with randomization listings will be stored in a secure environment within the Hospital. Blinding should be maintained throughout the study. The randomization code should not be broken during the course of the study unless it is necessary for the safety of the subjects, as judged by the investigator. The date, time and reason for unmasking must be recorded, along with the researcher's signature. The rupture of the study blind will be done once the database has been blocked. The study will be double-blind, which means that neither the patients nor the study site staff will have access to the randomization code until the code is broken.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>30 Day Survival</measure>
    <time_frame>day 30</time_frame>
    <description>Better survival in patients with omega 5 supplement associated to prednisone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reponse to steroids at day 7</measure>
    <time_frame>day 7</time_frame>
    <description>To describe the response to steroids (Lille score) at 7 days of treatment in patients with severe alcoholic hepatitis with combined treatment (Omega 5 and steroids) compared to standard treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde serum levels</measure>
    <time_frame>basal, day 7, day 14 and day 28</time_frame>
    <description>To determine the serum concentrations of lipid peroxidation molecules (malondialdehyde (MDA expressed in mM) in patients with severe alcoholic hepatitis treated with prednisone compare to those treated with prednisona and omega5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress molecules serum levels</measure>
    <time_frame>basal, day 7, day 14 and day 28</time_frame>
    <description>To analyze changes in oxidative stress markers (Oxidative glutation and reduced glutation expressed in mM) in patients with severe alcoholic hepatitis treated with prednisone compared to those treated with prednisone and omega 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Omega 5 fatty acid supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 5 fatty acid supplement</intervention_name>
    <description>Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.</description>
    <arm_group_label>Omega 5 fatty acid supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical and biochemical criteria for severe alcoholic hepatitis (Total
             bilirubin greater than 5 mg/dl in absence of biliary tract obstruction evidenced by
             ultrasound, history of chronic alcohol intake (greater than 50 g / day for at least 3
             months), leukocytosis, neutrophilia, elevation of transaminases with an aspartate
             aminotransferase / alanine aminotransferase ratio equal or greater than 2),
             discriminant function greater than 32.

        Exclusion Criteria:

          -  Hepatorenal syndrome,

          -  Hepatocellular carcinoma.

          -  Hepatitis C virus, hepatitis B virus or human immunodeficiency virus infection.

          -  Cancer, heart disease, neurological or severe neurological.

          -  Patients taking pentoxifylline, steroids, S-adenosyl L- methionine or
             N-Acetylcysteine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Cordova-Gallardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Dr. Manuel Gea Gonzalez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriela Gutierrez-Reyes, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma de México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Cordova-Gallardo, MD</last_name>
    <phone>+525540003000</phone>
    <email>jacquiemex2@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriela Gutierrez-Reyes, DSc</last_name>
    <phone>525556232673</phone>
    <email>gabgurey@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratorio de Higado, Pancreas y Motilidad Intestinal. UNIVERSIDAD AUTONOMA DE MEXICO</name>
      <address>
        <city>Mexico City</city>
        <state>Cuauhtemoc</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Gutierrez-Reyes, DSc</last_name>
      <phone>+525556232673</phone>
      <email>gabgurey@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela Gutierrez-Reyes, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorothy Rosique-Oramas, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaira Medina-Avila, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Dr. Manuel Gea Gonzalez</name>
      <address>
        <city>Mexico City</city>
        <state>Tlalpan</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Cordova-Gallardo, MD</last_name>
      <phone>525540003000</phone>
      <phone_ext>1239</phone_ext>
      <email>jacquiemex2@yahoo.com.mx</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Cordova-Gallardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Munguia-Ramos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Karina Tenorio-Aguirre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Vazquez-Cardenas, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Lopez-Gomez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yenisey Yadkinnie-Cruz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012 Aug;57(2):399-420. doi: 10.1016/j.jhep.2012.04.004. Epub 2012 May 26.</citation>
    <PMID>22633836</PMID>
  </reference>
  <reference>
    <citation>Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol. 2005 Jan-Mar;4(1):52-5.</citation>
    <PMID>15798662</PMID>
  </reference>
  <reference>
    <citation>Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol. 2010 Oct 21;16(39):4905-12. Review.</citation>
    <PMID>20954276</PMID>
  </reference>
  <reference>
    <citation>Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review.</citation>
    <PMID>19553649</PMID>
  </reference>
  <reference>
    <citation>Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214.</citation>
    <PMID>22070475</PMID>
  </reference>
  <reference>
    <citation>Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-28. doi: 10.1056/NEJMoa1412278.</citation>
    <PMID>25901427</PMID>
  </reference>
  <reference>
    <citation>Basra G, Basra S, Parupudi S. Symptoms and signs of acute alcoholic hepatitis. World J Hepatol. 2011 May 27;3(5):118-20. doi: 10.4254/wjh.v3.i5.118.</citation>
    <PMID>21731904</PMID>
  </reference>
  <reference>
    <citation>Sass DA, Shaikh OS. Alcoholic hepatitis. Clin Liver Dis. 2006 May;10(2):219-37, vii. Review.</citation>
    <PMID>16971259</PMID>
  </reference>
  <reference>
    <citation>Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. doi: 10.1155/2012/853175. Epub 2012 Mar 1.</citation>
    <PMID>22500241</PMID>
  </reference>
  <reference>
    <citation>Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis. 2005 Feb;9(1):37-53. Review.</citation>
    <PMID>15763228</PMID>
  </reference>
  <reference>
    <citation>Dugum MF, McCullough AJ. Acute Alcoholic Hepatitis, the Clinical Aspects. Clin Liver Dis. 2016 Aug;20(3):499-508. doi: 10.1016/j.cld.2016.02.008. Epub 2016 May 14. Review.</citation>
    <PMID>27373612</PMID>
  </reference>
  <reference>
    <citation>Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009 Jul;30(1):3-13. doi: 10.1111/j.1365-2036.2009.04002.x. Epub 2009 Mar 26. Review.</citation>
    <PMID>19416132</PMID>
  </reference>
  <reference>
    <citation>Gholam PM. Prognosis and Prognostic Scoring Models for Alcoholic Liver Disease and Acute Alcoholic Hepatitis. Clin Liver Dis. 2016 Aug;20(3):491-7. doi: 10.1016/j.cld.2016.02.007. Epub 2016 May 14. Review.</citation>
    <PMID>27373611</PMID>
  </reference>
  <reference>
    <citation>Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2:2. Epub 2002 Jan 22.</citation>
    <PMID>11835693</PMID>
  </reference>
  <reference>
    <citation>Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008 Nov;103(11):2747-56. doi: 10.1111/j.1572-0241.2008.02104.x. Epub 2008 Aug 21.</citation>
    <PMID>18721242</PMID>
  </reference>
  <reference>
    <citation>Higuera-de la Tijera MF, Pérez-Hernández JL, Serralde-Zúñiga AE, Servín-Caamaño AI, Cruz-Palacios A, Bernal-Sahagún F, Salas-Gordillo F. [Three prognostic utility scales to determine early mortality in patients with alcoholic hepatitis in the General Hospital of Mexico]. Rev Gastroenterol Mex. 2010;75(3):281-6. Spanish.</citation>
    <PMID>20959177</PMID>
  </reference>
  <reference>
    <citation>Altamirano J, Higuera-de laTijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG, Herrera-Jiménez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González JA, Cardenas A, Dominguez M, Arroyo V, Ginès P, Caballería J, Bataller R. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol. 2011 Aug;106(8):1472-80. doi: 10.1038/ajg.2011.141. Epub 2011 May 10.</citation>
    <PMID>21556041</PMID>
  </reference>
  <reference>
    <citation>Higuera-de la Tijera MF, Pérez-Hernández JL, Servín-Caamaño AL, Serralde-Zúñiga AE, Cruz-Palacios A. [The amount of alcohol intake, upper gastrointestinal bleeding, acute renal failure and hepatic encephalopathy as the risk factors implied in the increase of patients with alcoholic hepatitis]. Rev Gastroenterol Mex. 2009 Oct-Dec;74(4):306-13. Spanish.</citation>
    <PMID>20423759</PMID>
  </reference>
  <reference>
    <citation>Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.</citation>
    <PMID>19445945</PMID>
  </reference>
  <reference>
    <citation>Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.</citation>
    <PMID>17518367</PMID>
  </reference>
  <reference>
    <citation>Phillips PK, Lucey MR. Acute Alcoholic Hepatitis: Therapy. Clin Liver Dis. 2016 Aug;20(3):509-19. doi: 10.1016/j.cld.2016.02.015. Epub 2016 May 31. Review.</citation>
    <PMID>27373613</PMID>
  </reference>
  <reference>
    <citation>Higuera-de la Tijera F, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, Salas-Gordillo F, Pérez-Hernández JL. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015 Apr 28;21(16):4975-85. doi: 10.3748/wjg.v21.i16.4975.</citation>
    <PMID>25945012</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. doi: 10.1136/gut.2010.224097. Epub 2010 Oct 12.</citation>
    <PMID>20940288</PMID>
  </reference>
  <results_reference>
    <citation>Bihamta M, Hosseini A, Ghorbani A, Boroushaki MT. Protective effect of pomegranate seed oil against H(2)O(2) -induced oxidative stress in cardiomyocytes. Avicenna J Phytomed. 2017 Jan-Feb;7(1):46-53.</citation>
    <PMID>28265546</PMID>
  </results_reference>
  <results_reference>
    <citation>Boroushaki MT, Hosseini A, Dolati K, Mollazadeh H, Rajabian A. PROTECTIVE EFFECT OF POMEGRANATE SEED OIL AGAINST MERCURIC CHLORIDE-INDUCED HEPATOTOXICITY IN RAT. Acta Pol Pharm. 2016 Jul;73(4):991-997.</citation>
    <PMID>29648725</PMID>
  </results_reference>
  <results_reference>
    <citation>Boroushaki MT, Rajabian A, Farzadnia M, Hoseini A, Poorlashkari M, Taghavi A, Dolati K, Bazmandegan G. Protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren Fail. 2015;37(8):1338-43. doi: 10.3109/0886022X.2015.1073496. Epub 2015 Aug 14.</citation>
    <PMID>26288026</PMID>
  </results_reference>
  <results_reference>
    <citation>Nematbakhsh M. Cisplatin and herbal antioxidants: protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren Fail. 2016;38(2):344-5. doi: 10.3109/0886022X.2015.1127740. Epub 2015 Dec 27.</citation>
    <PMID>26707061</PMID>
  </results_reference>
  <results_reference>
    <citation>Boroushaki MT, Mollazadeh H, Rajabian A, Dolati K, Hoseini A, Paseban M, Farzadnia M. Protective effect of pomegranate seed oil against mercuric chloride-induced nephrotoxicity in rat. Ren Fail. 2014 Nov;36(10):1581-6. doi: 10.3109/0886022X.2014.949770. Epub 2014 Aug 26.</citation>
    <PMID>25154291</PMID>
  </results_reference>
  <results_reference>
    <citation>Boroushaki MT, Rajabian A, Farzadnia M, Hoseini A, Poorlashkari M, Taghavi A, Dolati K, Bazmandegan G. Protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren Fail. 2015 Aug 14:1-6. [Epub ahead of print]</citation>
    <PMID>26275112</PMID>
  </results_reference>
  <results_reference>
    <citation>Mollazadeh H, Sadeghnia HR, Hoseini A, Farzadnia M, Boroushaki MT. Effects of pomegranate seed oil on oxidative stress markers, serum biochemical parameters and pathological findings in kidney and heart of streptozotocin-induced diabetic rats. Ren Fail. 2016 Sep;38(8):1256-66. doi: 10.1080/0886022X.2016.1207053. Epub 2016 Jul 25.</citation>
    <PMID>27453190</PMID>
  </results_reference>
  <results_reference>
    <citation>Boroushaki MT, Arshadi D, Jalili-Rasti H, Asadpour E, Hosseini A. Protective effect of pomegranate seed oil against acute toxicity of diazinon in rat kidney. Iran J Pharm Res. 2013 Fall;12(4):821-7.</citation>
    <PMID>24523762</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaban NZ, El-Kersh MA, El-Rashidy FH, Habashy NH. Protective role of Punica granatum (pomegranate) peel and seed oil extracts on diethylnitrosamine and phenobarbital-induced hepatic injury in male rats. Food Chem. 2013 Dec 1;141(3):1587-96. doi: 10.1016/j.foodchem.2013.04.134. Epub 2013 May 23.</citation>
    <PMID>23870864</PMID>
  </results_reference>
  <results_reference>
    <citation>Coursodon-Boyiddle CF, Snarrenberg CL, Adkins-Rieck CK, Bassaganya-Riera J, Hontecillas R, Lawrence P, Brenna JT, Jouni ZE, Dvorak B. Pomegranate seed oil reduces intestinal damage in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G744-51. doi: 10.1152/ajpgi.00248.2012. Epub 2012 Jul 19.</citation>
    <PMID>22821948</PMID>
  </results_reference>
  <results_reference>
    <citation>Mollazadeh H, Boroushaki MT, Soukhtanloo M, Afshari AR, Vahedi MM. Effects of pomegranate seed oil on oxidant/antioxidant balance in heart and kidney homogenates and mitochondria of diabetic rats and high glucose-treated H9c2 cell line. Avicenna J Phytomed. 2017 Jul-Aug;7(4):317-333.</citation>
    <PMID>28884082</PMID>
  </results_reference>
  <results_reference>
    <citation>Cao Y, Yang L, Gao HL, Chen JN, Chen ZY, Ren QS. Re-characterization of three conjugated linolenic acid isomers by GC-MS and NMR. Chem Phys Lipids. 2007 Feb;145(2):128-33. Epub 2006 Dec 1.</citation>
    <PMID>17204261</PMID>
  </results_reference>
  <results_reference>
    <citation>Baccarin T, Mitjans M, Ramos D, Lemos-Senna E, Vinardell MP. Photoprotection by Punica granatum seed oil nanoemulsion entrapping polyphenol-rich ethyl acetate fraction against UVB-induced DNA damage in human keratinocyte (HaCaT) cell line. J Photochem Photobiol B. 2015 Dec;153:127-36. doi: 10.1016/j.jphotobiol.2015.09.005. Epub 2015 Sep 4.</citation>
    <PMID>26406978</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirmiran P, Fazeli MR, Asghari G, Shafiee A, Azizi F. Effect of pomegranate seed oil on hyperlipidaemic subjects: a double-blind placebo-controlled clinical trial. Br J Nutr. 2010 Aug;104(3):402-6. doi: 10.1017/S0007114510000504. Epub 2010 Mar 25.</citation>
    <PMID>20334708</PMID>
  </results_reference>
  <results_reference>
    <citation>Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med. 2013;2013:789764. doi: 10.1155/2013/789764. Epub 2013 Apr 30.</citation>
    <PMID>23737845</PMID>
  </results_reference>
  <results_reference>
    <citation>Arao K, Yotsumoto H, Han SY, Nagao K, Yanagita T. The 9cis,11trans,13cis isomer of conjugated linolenic acid reduces apolipoprotein B100 secretion and triacylglycerol synthesis in HepG2 cells. Biosci Biotechnol Biochem. 2004 Dec;68(12):2643-5.</citation>
    <PMID>15618643</PMID>
  </results_reference>
  <results_reference>
    <citation>Baccarin T, Mitjans M, Lemos-Senna E, Vinardell MP. Protection against oxidative damage in human erythrocytes and preliminary photosafety assessment of Punica granatum seed oil nanoemulsions entrapping polyphenol-rich ethyl acetate fraction. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):421-8. doi: 10.1016/j.tiv.2015.09.020. Epub 2015 Sep 25.</citation>
    <PMID>26407526</PMID>
  </results_reference>
  <results_reference>
    <citation>Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, Fainstein N, Ovadia H, Ben-Hur T, Magdassi S, Gabizon R. Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. Nanomedicine. 2014 Aug;10(6):1353-63. doi: 10.1016/j.nano.2014.03.015. Epub 2014 Apr 2.</citation>
    <PMID>24704590</PMID>
  </results_reference>
  <results_reference>
    <citation>Harzallah A, Hammami M, Kępczyńska MA, Hislop DC, Arch JR, Cawthorne MA, Zaibi MS. Comparison of potential preventive effects of pomegranate flower, peel and seed oil on insulin resistance and inflammation in high-fat and high-sucrose diet-induced obesity mice model. Arch Physiol Biochem. 2016;122(2):75-87. doi: 10.3109/13813455.2016.1148053. Epub 2016 Feb 26.</citation>
    <PMID>26822470</PMID>
  </results_reference>
  <results_reference>
    <citation>Miranda J, Arias N, Fernández-Quintela A, del Puy Portillo M. Are conjugated linolenic acid isomers an alternative to conjugated linoleic acid isomers in obesity prevention? Endocrinol Nutr. 2014 Apr;61(4):209-19. doi: 10.1016/j.endonu.2013.04.016. Epub 2013 Sep 10. Review. English, Spanish.</citation>
    <PMID>24029409</PMID>
  </results_reference>
  <results_reference>
    <citation>Holic R, Xu Y, Caldo KMP, Singer SD, Field CJ, Weselake RJ, Chen G. Bioactivity and biotechnological production of punicic acid. Appl Microbiol Biotechnol. 2018 Apr;102(8):3537-3549. doi: 10.1007/s00253-018-8883-y. Epub 2018 Mar 3. Review.</citation>
    <PMID>29502183</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Dr. Manuel Gea González</investigator_affiliation>
    <investigator_full_name>Jacqueline Cordova-Gallardo</investigator_full_name>
    <investigator_title>Hepatologist</investigator_title>
  </responsible_party>
  <keyword>Severe Alcoholic Hepatitis treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The results will be shared in international medical meetings</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

